What do you think of this one, and the generic pharma's in general. It seems HZNP isn't expensive at a 10 PE on 2019 estimates, with 18% EPS growth expected.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.